Literature DB >> 24126544

Bariatric and metabolic surgery.

M Fried1.   

Abstract

In the beginning of the 21st century obesity still represents health, social and economical threat for most of economically wealthy countries worldwide. Estimated direct costs for obesity and related comorbidities treatment exceed 5% of the total health care costs both in the US and in European Union. However, in addition there are obesity-related indirect costs linked to more frequent work sickness leave, higher unemployment rates and overall lower productivity of obese patients. Surgical treatment of obesity (bariatric surgery) is the most effective long-term treatment modality for those patients suffering from higher degrees of obesity. Bariatric surgery has not only positive effects on weight loss, but is also extremely effective in improving or resolving many of obesity-related comorbidities, which have evolved rapidly into the so-called metabolic surgery. T2DM may serve as excellent example of metabolic, obesity-related comorbidity which can be treated with bariatric-metabolic procedure even without direct relation to weight loss. In such cases bariatric surgery evolves into metabolic surgery. Thus metabolic operations (namely from the malabsorptive end) deeply influence hormonal secretion especially in the proximal part of small bowel, change parametres of entero-insular axis and have positive influence on insulin secretion, sensitivity and on the entire complex of glucose tolerance. Nowadays we can witness dramatic changes in perception of T2DM from bariatric surgeons, diabetologists, and many other medical specialists. T2DM has evolved from primarily medical disease into a condition where surgeons may play a more active role in the management of the diabetic patient. However, it has to be stressed that metabolic treatment of T2DM and other metabolic disorders need multidisciplinary approach and collaboration and that surgeon should play very important role as a multidisciplinary team member, however metabolic surgery should not yet be considered as stand-alone treatment modality.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24126544

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  2 in total

1.  Influence of excess weight loss and weight regain on biochemical indicators during a 4-year follow-up after Roux-en-Y gastric bypass.

Authors:  Carolina Ferreira Nicoletti; Bruno Affonso Parenti de Oliveira; Marcela Augusta Souza de Pinhel; Bruna Donati; Julio Sergio Marchini; Wilson Salgado Junior; Carla Barbosa Nonino
Journal:  Obes Surg       Date:  2015-02       Impact factor: 4.129

2.  Insulin Sensitivity and Secretion in Obese Type 2 Diabetic Women after Various Bariatric Operations.

Authors:  Jana Vrbikova; Marie Kunesova; Ioannis Kyrou; Andrea Tura; Martin Hill; Tereza Grimmichova; Katerina Dvorakova; Petra Sramkova; Karin Dolezalova; Olga Lischkova; Josef Vcelak; Vojtech Hainer; Bela Bendlova; Sudhesh Kumar; Martin Fried
Journal:  Obes Facts       Date:  2016-12-13       Impact factor: 3.942

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.